ストックスクリーナーアプリを入手
16.20
33.87%
-8.2506
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Sarepta Therapeutics Stock Tumbles After Trial Data - Schaeffer's Investment Research
Sarepta (SRPT) Stock Plummets Over 30% - GuruFocus
Sarepta shares tumble on trial failure, weak Elevidys outlook - Reuters
Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ - 富途牛牛
Palantir, Sarepta, Uber, Pfizer, Tesla, Norwegian Cruise Line, AMD, and More Movers - Barron's
Sarepta Therapeutics (SRPT) Stock: Clinical Failure Triggers Massive Selloff - parameter.io
Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo! Finance UK
Sarepta Duchenne drugs come up short in confirmatory test - BioPharma Dive
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat (NASDAQ:SRPT) - Seeking Alpha
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters - BioSpace
Stocks making the biggest moves premarket: Uber, Sarepta, Palantir, Norwegian Cruise and more - CNBC
Sarepta shares slide as DMD treatment woes pile up - pharmaphorum
Needham Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating - 富途牛牛
Sarepta Says Older Muscle Disease Drugs Failed Confirmatory Trial - Bloomberg.com
Sarepta Earnings Beat Expectations. Why the Stock Is Down 40%. - Barron's
Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More Movers - Barron's
Morning Market Movers: DENN, SRPT, JELD, ICHR See Big Swings - RTTNews
Sell Rating for Sarepta Therapeutics Amid ESSENCE Study Disappointment and Reimbursement Concerns - TipRanks
Two of Sarepta’s DMD drugs fail to meet primary endpoint in confirmatory trial - Yahoo Finance
Multi asset correlation models including Sarepta Therapeutics Inc.Weekly Stock Analysis & Community Consensus Picks - newser.com
Relative strength of Sarepta Therapeutics Inc. in sector analysisPortfolio Return Report & Long-Term Growth Plans - newser.com
Sarepta Stock Tumbles 40%. Why the Biotech’s Shares Are Sinking. - MSN
Dow Futures Edge Lower On Pullback Fears: PLTR, SRPT, TSLA, AMD Among Stocks To Watch - Stocktwits
Baird lowers Sarepta Therapeutics stock price target to $15 on ESSENCE trial failure - Investing.com Nigeria
Analyzing drawdowns of Sarepta Therapeutics Inc. with statistical toolsTrade Analysis Report & Risk Controlled Daily Trade Plans - newser.com
Palantir, Sarepta, Tesla, Amazon, AMD, Pfizer, and More Stock Market Movers - Barron's
Palantir, Sarepta, Amazon, AMD, Pfizer, and More Stock Market Movers - Barron's
Sarepta Therapeutics (SRPT) Stock Crashes as Nine-Year Trial Ends in Disappointment - CoinCentral
Biggest stock movers Tuesday: PLTR, SRPT, and more (NASDAQ:PLTR) - Seeking Alpha
Sarepta slumps as gene therapy setback adds to drug pipeline woes - Yahoo Finance
Pinnacle Associates Ltd. Has $997,000 Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Stocks to Watch Tuesday: Palantir, Sarepta, Tesla - The Wall Street Journal
Is Sarepta Therapeutics Inc. stock supported by strong cash flowsJuly 2025 Levels & Risk Managed Investment Signals - newser.com
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025July 2025 Gainers & Consistent Income Trade Ideas - newser.com
Will Sarepta Therapeutics Inc. stock benefit from sector rotationQuarterly Market Review & Technical Confirmation Alerts - newser.com
Sarepta Therapeutics Swings to Q3 Adjusted Loss, Revenue Falls; Shares Down Pre-Bell - MarketScreener
What technical charts say about Sarepta Therapeutics Inc. stockJuly 2025 Macro Moves & High Accuracy Investment Signals - newser.com
What technical models suggest about Sarepta Therapeutics Inc.’s comeback - newser.com
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - Stocktwits
Sarepta Therapeutics (SRPT) to Join S&P SmallCap 600 - GuruFocus
Why Sarepta Therapeutics Shares Tumbled Today - TipRanks
Why Is Sarepta Stock (SRPT) Crashing in Pre-Market Today? - TipRanks
Earnings Snapshot: Sarepta Q3 beat; ESSENCE study did not meet statistical significance on primary endpoint - MSN
Sarepta Therapeutics Inc (SRPT) Q3 2025 Earnings Call Highlights: Resilient Revenue Amidst ... - Yahoo Finance
Sarepta Therapeutics Stock Crashes After-Hours On DMD Trial Failure, Q3 Print — Retail Still Sees Long-Term Comeback - Stocktwits
Sarepta Therapeutics Reports Q3 2025 Financial Results - TipRanks
Transcript : Sarepta Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE - BioSpace
Sarepta Therapeutics (SRPT): Assessing Valuation After Q3 Earnings Reveal Swing to Net Loss - simplywall.st
Sarepta's shares sink after antisense DMD therapies fail confirmatory trial - FirstWord Pharma
Sarepta Therapeutics: Q3 Earnings Snapshot - CTPost
Sarepta Therapeutics Outpaces Forecasts On Gene Therapy Strength - Finimize
Earnings call transcript: Sarepta Therapeutics beats Q3 2025 EPS forecast - Investing.com
Sarepta's shares plunge after trial for muscle-wasting disease drugs miss key goal - Reuters
Sarepta Therapeutics Stock: Strong Q3 and ESSENCE Study Results Propel Future Growth Plans - parameter.io
Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success - MarketWatch
Sarepta Therapeutics (SRPT) Shares Plunge 20% After Trial Setbac - GuruFocus
Sarepta Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
Sarepta Therapeutics (SRPT) Beats Q3 Earnings Expectations Despi - GuruFocus
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina - Investing.com Nigeria
Sarepta plunges after late-stage Duchenne trial failure - MSN
1.53%
0.27%
大文字化:
|
ボリューム (24 時間):